Full text
Earnings transcript
Read the complete earnings call transcript.
TMO
Thermo Fisher Scientific Inc.
$690
-6.49
(-0.93%)
| Exchange: | NYSE |
| Market Cap: | 255.126B |
| Shares Outstanding: | 48.801M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – Diagnostics & ResearchView industry performance | |||||
| CEO: | Marc N. Casper | |||||
| Full Time Employees: | 125000 | |||||
| Address: |
| |||||
| Website: | https://www.thermofisher.com |
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company’s reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company’s products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
Click to read more…
Revenue Segmentation
TMO full analysis
Hey everyone, welcome back to MarketSnap. Thermo Fisher just delivered a blowout quarter, raised guidance, and the stock still trades below where our models think it should — but here's the catch: the market is pricing in a growth slowdown that could either be a massive buying opportunity or a value trap in disguise. Today we're stress-testing TMO with MarketSnap's valuation engine — not the hype, just the math. Before we dive into the numbers, let's set the stage. Thermo…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 42,857,000 | 42,879,000 | 44,557,000 |
| Gross Profit | 17,194,000 | 17,728,000 | 18,239,000 |
| EBITDA | 11,195,000 | 11,800,000 | 11,466,000 |
| Operating Income | 7,446,000 | 7,662,000 | 8,109,000 |
| Net Income | 5,995,000 | 6,335,000 | 6,737,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 98,726,000 | 97,321,000 | 110,343,000 |
| Total Liabilities | 51,884,000 | 47,650,000 | 56,807,000 |
| Total Stockholders Equity | 46,735,000 | 49,584,000 | 53,415,000 |
| Total Debt | 36,424,000 | 32,775,000 | 39,385,000 |
| Cash and Cash Equivalents | 8,083,000 | 4,009,000 | 9,852,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 8,406,000 | 8,667,000 | 7,818,000 |
| Capital Expenditure | -1,479,000 | -1,400,000 | -1,525,000 |
| Free Cash Flow | 6,927,000 | 7,267,000 | 6,293,000 |
| Net Income | 5,995,000 | 6,338,000 | 6,721,000 |
| Net Change in Cash | -440,000 | -4,057,000 | 5,839,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 58,302,518.682 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 59,727,706.370 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 58,775,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 19,599,267.792 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 20,095,503.616 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 19,763,781.472 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 14,252,764.017 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 14,706,792.659 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 14,403,285.038 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 11,625,631.707 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 11,909,816.809 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 11,719,845.369 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 38.210 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 39.010 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 37.810 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 14 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 2 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: TMO demonstrates strong revenue and net income figures in recent income statements, supported by consistent growth in operating cash flow and free cash flow as per cash flow statements. This indicates a solid operational foundation and ability to generate sustainable cash for reinvestment or shareholder returns.
- Market Leadership in Sector: As part of the healthcare equipment and services industry within the broader healthcare sector, TMO benefits from a strong market position, reflected in its substantial market capitalization and consistent performance metrics (perf1y, perf5y) that often outperform industry averages (industry_perf1y, industry_perf5y).
- High Profitability Metrics: Key metrics such as gross profit margin (grossProfitMarginTTM) and net profit margin (netProfitMarginTTM) are indicative of efficient cost management and pricing power, positioning TMO favorably against competitors in the sector.
- Strong Balance Sheet: The balance sheet data highlights a healthy level of cash and cash equivalents alongside manageable total liabilities relative to total assets, suggesting financial stability and resilience (totalCurrentAssets, totalLiabilities, totalStockholdersEquity).
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates TMO intrinsic value between $543.59 – $549.57 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about TMO valuation
Is Thermo Fisher Scientific Inc. (TMO) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Thermo Fisher Scientific Inc. (TMO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is TMO a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TMO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is TMO’s P/E ratio?
You can see TMO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for TMO?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is TMO a good long-term investment?
Whether TMO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
TMO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.93
Trading Metrics:
| Open: | 692.26 | Previous Close: | 696.49 | |
| Day Low: | 683.63 | Day High: | 699.2 | |
| Year Low: | 435.27 | Year High: | 704 | |
| Price Avg 50: | 634.49 | Price Avg 200: | 546.79 | |
| Volume: | 2.089M | Average Volume: | 2.13M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
